NewsAnalysisPodcastsLearningCommunityOpens in new windowJobsOpens in new windowC+D AwardsOpens in new windowDataOpens in new window

Crimes in pharmacies

Partnered Content

Jobs

Find a jobOpens in new window

Post a jobOpens in new window

C+D AwardsOpens in new window

LoginOpens in new window

Data servicesOpens in new window

Pharmacy subscriptions

More

Advertise with us

Home

Maxwellia addresses criticism of mooted oxybutynin drug reclassification

Apr 27 2022

• By Valeria Fiore and Eliza Loukou

MHRA consultation — The proposed POM to P switch was met with criticism from some healthcare professionals

Additional Topics

Medicines Womens health Social Issues

Latest from News

More from Clinical

Facebook page Twitter feed RSS feed RSS feed

Discover More

C+D DataOpens in new window
C+D CommunityOpens in new window
C+D JobsOpens in new window

C+D has been informing, supporting and championing community pharmacy since 1859 and is proud to be at the forefront of providing the latest news to everyone working in the sector.

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Community Principles

Copyright © 2025 Citeline, a Norstella Company. Chemist+Druggist is a trading division of Citeline, a Norstella company and operates as part of C&D Intelligence U.K. Limited. C&D Intelligence U.K. Limited is a company registered in England and Wales (Registration number 13793264) with its registered office at 3 More London Riverside, London SE1 2AQ.